A research brief published today in the online edition of the journal Cancer Discovery, provides clinical evidence for the utility of comprehensive genomic profiling in matching patients to targeted therapy clinical trials. A female patient with advanced soft tissue sarcoma widely metastatic to the lungs had a tumor specimen submitted to Foundation Medicine by her physician following multiple unsuccessful courses of treatment. Testing with FoundationOne® Heme – our comprehensive genomic profiling assay for in hematologic malignancies and sarcomas – found that her cancer harbored a TRK gene fusion. She was referred to the University of Colorado Cancer Center for enrollment in the Phase 1 trial of LOXO-101, a selective TRK inhibitor developed by Loxo Oncology, which is currently being studied in patients with advanced solid tumors.
On the study, the patient’s shortness of breath rapidly resolved, and she was able to discontinue her supplemental oxygen and resume normal daily living and activities. Lead author, Robert C. Doebele, M.D., Ph.D., associate professor, division of medical oncology, University of Colorado Cancer Center said, “this case study also illustrated the clinical value of multiplex genetic testing in patients with advanced cancer. Broad testing for all known actionable molecular alterations gives patients the best opportunity to find commercially available or investigational targeted therapies that have been rationally designed to treat their cancers.”
This research further supports our strong belief that comprehensive genomic profiling should be incorporated into routine clinical care, including the process of selecting and providing access to appropriate clinical trials that would otherwise not have been considered.